GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Price-to-Free-Cash-Flow
中文

Daiichinkyo Co (Daiichinkyo Co) Price-to-Free-Cash-Flow : 16.50 (As of Apr. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Price-to-Free-Cash-Flow?

As of today (2024-04-25), Daiichinkyo Co's share price is $30.50. Daiichinkyo Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.85. Hence, Daiichinkyo Co's Price-to-Free-Cash-Flow Ratio for today is 16.50.

The historical rank and industry rank for Daiichinkyo Co's Price-to-Free-Cash-Flow or its related term are showing as below:

DSNKY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.21   Med: 44   Max: 576.17
Current: 17.64

During the past 13 years, Daiichinkyo Co's highest Price-to-Free-Cash-Flow Ratio was 576.17. The lowest was 12.21. And the median was 44.00.

DSNKY's Price-to-Free-Cash-Flow is ranked better than
59.11% of 494 companies
in the Drug Manufacturers industry
Industry Median: 21.73 vs DSNKY: 17.64

Daiichinkyo Co's Free Cash Flow per Share for the three months ended in Dec. 2023 was $2.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $1.85.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Daiichinkyo Co was 864.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -30.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.30% per year.

During the past 13 years, Daiichinkyo Co's highest 3-Year average Free Cash Flow per Share Growth Rate was 92.50% per year. The lowest was -48.70% per year. And the median was 16.65% per year.


Daiichinkyo Co Price-to-Free-Cash-Flow Historical Data

The historical data trend for Daiichinkyo Co's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Price-to-Free-Cash-Flow Chart

Daiichinkyo Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.26 33.51 48.89 82.21 196.22

Daiichinkyo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.34 196.22 576.17 - 14.58

Competitive Comparison of Daiichinkyo Co's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Price-to-Free-Cash-Flow falls into.



Daiichinkyo Co Price-to-Free-Cash-Flow Calculation

Daiichinkyo Co's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=30.50/1.848
=16.50

Daiichinkyo Co's Share Price of today is $30.50.
Daiichinkyo Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Daiichinkyo Co  (OTCPK:DSNKY) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Daiichinkyo Co Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.